Oral semaglutide reduced ad libitum daily energy intake by 39% versus placebo in type 2 diabetes patients, with increased satiety after fatty meals, fewer cravings, and 2.7 kg weight loss from body fat.
39% less food intakeOral semaglutide 14mg reduced voluntary daily calorie consumption by 39% versus placebo, demonstrating genuine appetite suppression as the mechanism for weight loss
What the researchers found
Oral semaglutide 14mg reduced total daily ad libitum energy intake by 38.9% versus placebo (treatment difference -5,096 kJ, p=0.0001). Increased satiety and fullness after fat-rich breakfast. Body weight decreased 2.7 kg (mostly fat mass) vs 0.1 kg placebo.
Why it matters
Understanding exactly how GLP-1 drugs reduce food intake helps explain their weight loss effects and informs clinical use. The 39% calorie reduction explains the meaningful weight loss seen in larger trials.
The numbers in context
38.9% energy intake reduction; 5,096 kJ/day difference; 2.7 kg weight loss vs 0.1 kg; P=0.0001
How the study worked
Randomized, double-blind, placebo-controlled, two-period crossover trial. 15 subjects with T2D. 12 weeks oral semaglutide (escalated 3→7→14 mg) vs placebo. Ad libitum energy intake, appetite VAS ratings after standard and fat-rich breakfasts, Control of Eating Questionnaire, body composition.
Who was studied
Adults with type 2 diabetes
What this study cannot tell us
Very small study (15 subjects, 13 evaluable). Short duration (12 weeks). Crossover design in T2D patients — results may differ in non-diabetic obesity. Laboratory meal setting may not reflect real-world eating behavior.
How to read the evidence
Moderate evidence: randomized, double-blind, placebo-controlled crossover design, but very small sample (15 subjects).
When this study was published
Published 2021. Oral semaglutide (Rybelsus) is now widely prescribed, and its appetite effects are well-established in clinical practice.
The bigger picture
This mechanistic study demonstrates that oral semaglutide's weight loss is driven by genuine appetite suppression — reduced hunger, increased satiety, fewer cravings — rather than just gastrointestinal side effects. This supports the biological rationale for GLP-1 drugs as obesity treatments.
Questions still open
- Does the 39% calorie reduction persist with longer-term use or does tolerance develop?
- Which specific foods or macronutrients are most reduced by semaglutide?
- Would the appetite effects be similar in people without diabetes?
Common questions
Does semaglutide actually make you eat less?
Does the weight loss from semaglutide come from fat?
Read the original research
Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
Diabetes, obesity & metabolism, 23(2), 581-588
Citation
Gibbons, Catherine; Blundell, John; Tetens Hoff, Søren; Dahl, Kirsten; Bauer, Robert; Baekdal, Tine. (2021). Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.. Diabetes, obesity & metabolism, 23(2), 581-588. https://doi.org/10.1111/dom.14255